

Adriana Marques

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4982746/publications.pdf>

Version: 2024-02-01

87
papers

6,782
citations

94381

37
h-index

60583

81
g-index

92
all docs

92
docs citations

92
times ranked

4858
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and outcome of facial nerve palsy from Lyme neuroborreliosis in the United States. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 41-49.	1.7	12
2	Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by <i>Borrelia burgdorferi</i> . <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
3	A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. <i>Annals of Internal Medicine</i> , 2022, 175, 969-979.	2.0	99
4	Detection of antibodies to <i>Anaplasma phagocytophilum</i> and <i>Babesia microti</i> using linear peptides. <i>Ticks and Tick-borne Diseases</i> , 2022, 13, 101999.	1.1	1
5	Development of a capture sequencing assay for enhanced detection and genotyping of tick-borne pathogens. <i>Scientific Reports</i> , 2021, 11, 12384.	1.6	9
6	Comparison of Lyme Disease in the United States and Europe. <i>Emerging Infectious Diseases</i> , 2021, 27, 2017-2024.	2.0	99
7	Lack of Convincing Evidence that <i>Borrelia burgdorferi</i> Infection Causes Either Alzheimer's Disease or Lewy Body Dementia. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	2
8	Protective Immunity and New Vaccines for Lyme Disease. <i>Clinical Infectious Diseases</i> , 2020, 70, 1768-1773.	2.9	50
9	Identification of immunoreactive linear epitopes of <i>Borrelia miyamotoi</i> . <i>Ticks and Tick-borne Diseases</i> , 2020, 11, 101314.	1.1	25
10	Characterization of a <i>Monanema</i> nematode in <i>Ixodes scapularis</i> . <i>Parasites and Vectors</i> , 2020, 13, 371.	1.0	6
11	Usefulness of Routine Lyme Screening in Patients with Uveitis. <i>Ophthalmology</i> , 2019, 126, 1726-1728.	2.5	11
12	Post-treatment Lyme disease symptoms score: Developing a new tool for research. <i>PLoS ONE</i> , 2019, 14, e0225012.	1.1	10
13	A Multiplexed Serologic Test for Diagnosis of Lyme Disease for Point-of-Care Use. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	27
14	Direct Diagnostic Tests for Lyme Disease. <i>Clinical Infectious Diseases</i> , 2019, 68, 1052-1057.	2.9	60
15	A multiplex serologic platform for diagnosis of tick-borne diseases. <i>Scientific Reports</i> , 2018, 8, 3158.	1.6	68
16	Transcriptome Assessment of Erythema Migrans Skin Lesions in Patients With Early Lyme Disease Reveals Predominant Interferon Signaling. <i>Journal of Infectious Diseases</i> , 2018, 217, 158-167.	1.9	34
17	Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. <i>Clinical Infectious Diseases</i> , 2018, 66, 1133-1139.	2.9	82
18	Plasticity in early immune evasion strategies of a bacterial pathogen. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E3788-E3797.	3.3	29

#	ARTICLE	IF	CITATIONS
19	Reply to von Reyn and Horsburgh. <i>Clinical Infectious Diseases</i> , 2018, 67, 1308-1309.	2.9	1
20	C-Reactive Protein Response in Patients With Post-Treatment Lyme Disease Symptoms Versus Those With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. <i>Clinical Infectious Diseases</i> , 2018, 67, 1309-1310.	2.9	10
21	Revisiting the Lyme Disease Serodiagnostic Algorithm: the Momentum Gathers. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	34
22	Xenodiagnosis Using Ixodes scapularis Larval Ticks in Humans. <i>Methods in Molecular Biology</i> , 2018, 1690, 337-346.	0.4	3
23	Early Disseminated Lyme Disease Causing False-Positive Serology for Primary Epstein-Barr Virus Infection: Report of 2 Cases. <i>Clinical Infectious Diseases</i> , 2017, 65, 336-337.	2.9	12
24	Citrate Anticoagulant Improves the Sensitivity of <i>Borrelia</i> (<i>Borrelia</i>) burgdorferi Plasma Culture. <i>Journal of Clinical Microbiology</i> , 2017, 55, 3297-3299.	1.8	2
25	Cross-Species Interferon Signaling Boosts Microbicidal Activity within the Tick Vector. <i>Cell Host and Microbe</i> , 2016, 20, 91-98.	5.1	52
26	Long-term Follow-up of Patients With Lyme Disease: Longitudinal Analysis of Clinical and Quality-of-life Measures. <i>Clinical Infectious Diseases</i> , 2016, 62, 1546-1551.	2.9	46
27	Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease. <i>Clinical Infectious Diseases</i> , 2016, 63, 1399-1404.	2.9	26
28	Insights into <i>Borrelia miyamotoi</i> infection from an untreated case demonstrating relapsing fever, monocytosis and a positive C6 Lyme serology. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 93-96.	0.8	35
29	Epitope-Specific Evolution of Human B Cell Responses to <i>Borrelia burgdorferi</i> VlsE Protein from Early to Late Stages of Lyme Disease. <i>Journal of Immunology</i> , 2016, 196, 1036-1043.	0.4	20
30	Laboratory Diagnosis of Lyme Disease. <i>Infectious Disease Clinics of North America</i> , 2015, 29, 295-307.	1.9	99
31	Association of Immune Response to Endothelial Cell Growth Factor With Early Disseminated and Late Manifestations of Lyme Disease but Not Posttreatment Lyme Disease Syndrome: Figure 1.. <i>Clinical Infectious Diseases</i> , 2015, 61, civ638.	2.9	5
32	Long-term Persistence of Zoster Vaccine Efficacy. <i>Clinical Infectious Diseases</i> , 2015, 60, 900-909.	2.9	240
33	1348Immune response to endothelial cell growth factor is elevated during acute Lyme borreliosis but not in post-Lyme disease syndrome. <i>Open Forum Infectious Diseases</i> , 2014, 1, S353-S353.	0.4	0
34	1352Progression of Lyme Disease to Later Stages is Associated with Antibody Response Towards the Membrane-Proximal Domain of the VlsE Protein of <i>Borrelia burgdorferi</i> . <i>Open Forum Infectious Diseases</i> , 2014, 1, S354-S354.	0.4	0
35	Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases. <i>Journal of Immunology</i> , 2014, 192, 2551-2563.	0.4	130
36	Xenodiagnosis to Detect <i>Borrelia burgdorferi</i> Infection: A First-in-Human Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 937-945.	2.9	111

#	ARTICLE	IF	CITATIONS
37	Is there a place for xenodiagnosis in the clinic?. Expert Review of Anti-Infective Therapy, 2014, 12, 1307-1310.	2.0	5
38	Invariant natural killer T cells act as an extravascular cytotoxic barrier for joint-invading Lyme <i>Borrelia</i>. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13936-13941.	3.3	54
39	The Reply. American Journal of Medicine, 2014, 127, e11-e12.	0.6	0
40	Treatment Trials for Post-Lyme Disease Symptoms Revisited. American Journal of Medicine, 2013, 126, 665-669.	0.6	106
41	Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagnostic Microbiology and Infectious Disease, 2013, 75, 9-15.	0.8	137
42	Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster. Journal of Infectious Diseases, 2013, 208, 559-563.	1.9	36
43	Lack of Serum Antibodies against <i>Borrelia burgdorferi</i> in Children with Autism. Vaccine Journal, 2013, 20, 1092-1093.	3.2	6
44	Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clinical Infectious Diseases, 2012, 55, 1320-1328.	2.9	203
45	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood, 2011, 117, 5835-5849.	0.6	241
46	Epitope mapping of antibodies to VlsE protein of <i>Borrelia burgdorferi</i> in post-Lyme disease syndrome. Clinical Immunology, 2011, 141, 103-110.	1.4	36
47	Synthesis and antigenicity of BBGL-2 glycolipids of <i>Borrelia burgdorferi</i> , the causative agent of Lyme disease. Carbohydrate Research, 2011, 346, 1551-1563.	1.1	20
48	Anti- <i>Borrelia burgdorferi</i> Antibody Profile in Post-Lyme Disease Syndrome. Vaccine Journal, 2011, 18, 767-771.	3.2	46
49	Lyme Disease: A Review. Current Allergy and Asthma Reports, 2010, 10, 13-20.	2.4	66
50	Rapid, Simple, Quantitative, and Highly Sensitive Antibody Detection for Lyme Disease. Vaccine Journal, 2010, 17, 904-909.	3.2	48
51	Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers. Journal of Virology, 2009, 83, 11857-11861.	1.5	62
52	Natural Killer Cell Counts Are Not Different between Patients with Post-Lyme Disease Syndrome and Controls. Vaccine Journal, 2009, 16, 1249-1250.	3.2	54
53	Natural Killer Cells in Chronic Lyme Disease. Vaccine Journal, 2009, 16, 1704-1706.	3.2	4
54	Tick-borne Relapsing Fever and <i>Borrelia hermsii</i>, Los Angeles County, California, USA. Emerging Infectious Diseases, 2009, 15, 1026-1031.	2.0	58

#	ARTICLE	IF	CITATIONS
55	A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF REPEATED IV ANTIBIOTIC THERAPY FOR LYME ENCEPHALOPATHY PROLONGED LYME DISEASE TREATMENT: ENOUGH IS ENOUGH. <i>Neurology</i> , 2009, 72, 383-386.	1.5	5
56	Vaccination against Herpes Zoster and Postherpetic Neuralgia. <i>Journal of Infectious Diseases</i> , 2008, 197, S228-S236.	1.9	157
57	Chronic Lyme Disease: A Review. <i>Infectious Disease Clinics of North America</i> , 2008, 22, 341-360.	1.9	158
58	Relapsing Fever Borreliosis in Interleukin-10-Deficient Mice. <i>Infection and Immunity</i> , 2008, 76, 5508-5513.	1.0	9
59	Interleukin 10 Protects the Brain Microcirculation From Spirochetal Injury. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 976-983.	0.9	11
60	IL-10 Helps Control Pathogen Load during High-Level Bacteremia. <i>Journal of Immunology</i> , 2008, 181, 2076-2083.	0.4	26
61	Varicella-Zoster Virus-Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine. <i>Journal of Infectious Diseases</i> , 2008, 197, 825-835.	1.9	329
62	Cerebrospinal Fluid-Infiltrating CD4 + T Cells Recognize <i>Borrelia burgdorferi</i> Lysine-Enriched Protein Domains and Central Nervous System Autoantigens in Early Lyme Encephalitis. <i>Infection and Immunity</i> , 2007, 75, 243-251.	1.0	22
63	IL-10 protects the cerebral microcirculation from spirochetal injury. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 432.	0.9	0
64	High Production of CXCL13 in Blood and Brain During Persistent Infection With the Relapsing Fever Spirochete <i>Borrelia turicatae</i> . <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 208-217.	0.9	20
65	Role of Interleukin 10 during Persistent Infection with the Relapsing Fever Spirochete <i>Borrelia turicatae</i> . <i>American Journal of Pathology</i> , 2007, 170, 251-262.	1.9	20
66	<i>Borrelia burgdorferi</i> Induces TLR1 and TLR2 in Human Microglia and Peripheral Blood Monocytes but Differentially Regulates HLA-Class II Expression. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 540-548.	0.9	26
67	<i>Borrelia burgdorferi</i> Lipoprotein-Mediated TLR2 Stimulation Causes the Down-Regulation of TLR5 in Human Monocytes. <i>Journal of Infectious Diseases</i> , 2006, 193, 849-859.	1.9	49
68	A Decline in C 6 Antibody Titer Occurs in Successfully Treated Patients with Culture-Confirmed Early Localized or Early Disseminated Lyme Borreliosis. <i>Vaccine Journal</i> , 2005, 12, 1069-1074.	3.2	46
69	A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. <i>New England Journal of Medicine</i> , 2005, 352, 2271-2284.	13.9	2,197
70	Detection of Immune Complexes Is Not Independent of Detection of Antibodies in Lyme Disease Patients and Does Not Confirm Active Infection with <i>Borrelia burgdorferi</i> . <i>Vaccine Journal</i> , 2005, 12, 1036-1040.	3.2	19
71	Pre-treatment and post-treatment assessment of the C6 test in patients with persistent symptoms and a history of Lyme borreliosis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004, 23, 615-8.	1.3	38
72	C 6 Test as an Indicator of Therapy Outcome for Patients with Localized or Disseminated Lyme Borreliosis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4955-4960.	1.8	42

#	ARTICLE	IF	CITATIONS
73	Serodiagnosis of Lyme Disease by Kinetic Enzyme-Linked Immunosorbent Assay Using Recombinant VlsE1 or Peptide Antigens of <i>Borrelia burgdorferi</i> Compared with 2-Tiered Testing Using Whole-Cell Lysates. <i>Journal of Infectious Diseases</i> , 2003, 187, 1187-1199.	1.9	261
74	Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. <i>Brain</i> , 2003, 126, 20-31.	3.7	74
75	Audiologic Manifestations of Patients with Post-Treatment Lyme Disease Syndrome. <i>Ear and Hearing</i> , 2003, 24, 508-517.	1.0	16
76	Evaluation of the C6 Peptide Enzyme-Linked Immunosorbent Assay for Individuals Vaccinated with the Recombinant OspA Vaccine. <i>Journal of Clinical Microbiology</i> , 2002, 40, 2591-2593.	1.8	20
77	Molecular Mimicry and Antigen-Specific T Cell Responses in Multiple Sclerosis and Chronic CNS Lyme Disease. <i>Journal of Autoimmunity</i> , 2001, 16, 187-192.	3.0	61
78	Lyme disease: An update. <i>Current Allergy and Asthma Reports</i> , 2001, 1, 541-549.	2.4	9
79	Lack of association between HSV-1 DNA in the brain, Alzheimer's disease and apolipoprotein E4. <i>Journal of NeuroVirology</i> , 2001, 7, 82-83.	1.0	26
80	FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome. <i>Neurology</i> , 2001, 57, 1980-1985.	1.5	53
81	Culture of <i>Borrelia burgdorferi</i> . <i>Journal of Clinical Microbiology</i> , 2001, 39, 2747-2747.	1.8	22
82	Antibody Response to IR6, a Conserved Immunodominant Region of the VlsE Lipoprotein, Wanes Rapidly after Antibiotic Treatment of <i>Borrelia burgdorferi</i> Infection in Experimental Animals and in Humans. <i>Journal of Infectious Diseases</i> , 2001, 184, 870-878.	1.9	121
83	Lack of Evidence of <i>Borrelia</i> Involvement in Alzheimer's Disease. <i>Journal of Infectious Diseases</i> , 2000, 182, 1006-1007.	1.9	37
84	Herpes simplex type 2 infections—An update. <i>Disease-a-Month</i> , 2000, 46, 325-359.	0.4	11
85	Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. <i>Nature Medicine</i> , 1999, 5, 1375-1382.	15.2	216
86	Advances in the treatment of chronic hepatitis B virus infection. , 1998, 8, 223-234.		7
87	Suppurative Cutaneous Granulomata Caused by <i>Microascus cinereus</i> in a Patient with Chronic Granulomatous Disease. <i>Clinical Infectious Diseases</i> , 1995, 20, 110-114.	2.9	30